Pfizer Calls Out Kaiser Over Contradictory Neurontin Claims

Law360, New York (November 21, 2012, 5:59 PM EST) -- Aiming to scuttle a $142 million jury award in multidistrict litigation over pain drug Neurontin, Pfizer Inc. on Tuesday sharply criticized Kaiser Foundation Health Plan Inc. before the First Circuit, accusing the HMO operator of complaining about the medicine’s effectiveness while paying for it anyway.

In its reply brief, the drugmaker accused Kaiser of offering virtually no rebuttal to allegations it allowed Neurontin prescriptions even after learning of studies that cast doubt on the medication’s value. What’s more, Kaiser even covered Neurontin after filing a lawsuit...
To view the full article, register now.